Dopamine Hydrochloride Injection — FDA Drug Shortage

To Be Discontinued — Hospira, Inc., a Pfizer Company

The FDA lists a drug shortage record for Dopamine Hydrochloride Injection (injection) from Hospira, Inc., a Pfizer Company with status To Be Discontinued. The shortage was first posted on 08/27/2025.

Shortage Details

Status
To Be Discontinued
Company
Hospira, Inc., a Pfizer Company
Package NDC
0409-7809-24
Dosage Form
Injection
Presentation
Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)
Initial Posting
08/27/2025
Revised Date